Vaxcyte (PCVX) Amortization of Deferred Charges (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Amortization of Deferred Charges data on file, last reported at $2.9 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 51.56% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 9.06% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, down 4.28% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $2.9 million, up from $2.3 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for PCVX reached as high as $2.9 million in Q1 2026 and fell as low as $1.6 million in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $2.0 million across 5 years, with a median of $1.9 million in 2024.
• Across the five-year window, Amortization of Deferred Charges soared 892.78% in 2022 and fell 21.09% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.6 million in 2022, then climbed by 28.91% to $2.1 million in 2023, then fell by 6.75% to $1.9 million in 2024, then rose by 19.89% to $2.3 million in 2025, then climbed by 26.23% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $2.9 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.